Loading stock data…
Kairos Pharma (KAPA)
$0.36+0.01 (+2.00%)
Market ClosedLast close Jun 29
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kairos Pharma, Ltd. in the Healthcare sector is trading at $0.36 with a market capitalization of $10M. Wall Street consensus targets $8.00 (2 analysts), implying a +2140.9% move over the next 12 months. The stock is currently near its 52-week low of $0.33, remaining 53.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +2140.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.69M↓ | -$1.42M↑ | -$1.44M↑ | -$1.46M↓ | -$1.27M |
| Net Income | -$1.65M↓ | -$1.36M↑ | -$1.40M↑ | -$1.42M↓ | -$1.26M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-109.90%
Volume
Today's trading volume
58,295
Recent News
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
The trial consisted of subjects who had not responded to at least one form of hormone therapy previously.
Top Midday Gainers
Longevity Health (XAGE) shares almost doubled amid heavy trading after the company said late Monday